{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:02:08Z","timestamp":1782298928802,"version":"3.54.5"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.crohns.2011.10.006","type":"journal-article","created":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T21:36:50Z","timestamp":1320961010000},"page":"476-482","source":"Crossref","is-referenced-by-count":30,"title":["Mesalazine in left-sided ulcerative colitis: Efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing"],"prefix":"10.1093","volume":"6","author":[{"given":"Bernd","family":"Bokemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Hommes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Broberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2011.10.006_bb0005","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3109\/00365529709011217","article-title":"Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990\u201393","volume":"32","author":"Moum","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0010","first-page":"1079","article-title":"Incidence of ulcerative colitis 1980\u20131995. A prospective study in an urban population in Germany","volume":"37","author":"Timmer","year":"1999","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.crohns.2007.11.002","article-title":"European evidence-based consensus on the management of ulcerative colitis: current management","volume":"2","author":"Travis","year":"2008","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2011.10.006_bb0020","first-page":"263","article-title":"Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis","volume":"12","author":"Bitton","year":"2001","journal-title":"Semin Gastrointest Dis"},{"key":"10.1016\/j.crohns.2011.10.006_bb0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2011.10.006_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/00365529009091909","article-title":"Pharmaceutical development","volume":"172","author":"Osterwald","year":"1990","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.crohns.2011.10.006_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00365529609094572","article-title":"Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease","volume":"216","author":"Brynskov","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF03044864","article-title":"Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen","volume":"93","author":"Keller","year":"1998","journal-title":"Med Klin"},{"key":"10.1016\/j.crohns.2011.10.006_bb0045","first-page":"215","article-title":"Ulcerative colitis therapy: importance of delivery mechanisms","volume":"5","author":"Rochester","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"key":"10.1016\/j.crohns.2011.10.006_bb0050","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1023\/A:1026664105112","article-title":"Inflammation does not decrease intra-luminal pH in chronic inflammatory bowel disease","volume":"44","author":"Ewe","year":"1999","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2011.10.006_bb0055","first-page":"A681","article-title":"Gastrointestinal pH profiles in ulcerative colitis","volume":"102","author":"Raimundo","year":"1992","journal-title":"Gastroenterology"},{"issue":"Suppl. 2","key":"10.1016\/j.crohns.2011.10.006_bb0180","first-page":"A9","article-title":"Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH dependent 5-ASA containing capsules (abstract T34)","volume":"47","author":"Nugent","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2011.10.006_bb0065","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2036.1990.tb00499.x","article-title":"Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man","volume":"4","author":"Christensen","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2011.10.006_bb0070","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cgh.2009.04.004","article-title":"Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis","volume":"7","author":"Dignass","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0185","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1873-9946(09)60196-3","article-title":"P169 \u2014 higher remission rates in patients with once-daily dosing compared to twice daily-dosing. An analysis of compliance in the once-daily vs. twice-daily PODIUM trial with mesalazine (Pentasa\u00ae) sachets","volume":"3","author":"Bokemeyer","year":"2009","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2011.10.006_bb0080","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.mib.0000231495.92013.5e","article-title":"Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials","volume":"12","author":"Regueiro","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2011.10.006_bb0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2036.2009.04117.x","article-title":"Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol","volume":"30","author":"Prantera","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2011.10.006_bb0090","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2011.10.006_bb0095","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/j.1572-0241.2000.02180.x","article-title":"Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis","volume":"95","author":"Marshall","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0100","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.48.4.571","article-title":"Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs","volume":"48","author":"Nugent","year":"2001","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.crohns.2011.10.006_bb0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1440-1746.2010.06497.x","article-title":"Topical agents for idiopathic distal colitis and proctitis","volume":"26","author":"Lawrance","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2036.2010.04537.x","article-title":"Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis","volume":"33","author":"Kruis","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2011.10.006_bb0115","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gut.2007.138248","article-title":"Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis","volume":"57","author":"Kamm","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2011.10.006_bb0120","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort","volume":"133","author":"Fr\u00f8slie","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2011.10.006_bb0125","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/gut.2010.218180","article-title":"Current misunderstandings in the management of ulcerative colitis","volume":"60","author":"Ochsenk\u00fchn","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2011.10.006_bb0130","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ibd.20875","article-title":"Controversies in mucosal healing in ulcerative colitis","volume":"15","author":"Kane","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2011.10.006_bb0135","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/j.1572-0241.2005.00248.x","article-title":"Delayed-release oral mesalamine at 4.8g\/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial","volume":"100","author":"Hanauer","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0140","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1155\/2007\/862917","article-title":"Delayed-release oral mesalamine 4.8g\/day (800mg tablets) compared to 2.4g\/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial","volume":"21","author":"Hanauer","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2006.10.011","article-title":"Once-daily, high-concentration MMX mesalamine in active ulcerative colitis","volume":"132","author":"Hanauer","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2011.10.006_bb0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2006.10.025","article-title":"Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis","volume":"5","author":"Lichtenstein","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrgastro.2009.203","article-title":"Clinical implications of mucosal healing for the management of IBD","volume":"7","author":"Pineton de Chambrun","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2011.10.006_bb0160","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ibd.20997","article-title":"Importance of mucosal healing in ulcerative colitis","volume":"16","author":"Lichtenstein","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2011.10.006_bb0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort","volume":"133","author":"Froslie","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2011.10.006_bb0170","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/gut.2003.038505","article-title":"Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk","volume":"53","author":"Rutter","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2011.10.006_bb0175","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199011013231802","article-title":"Ulcerative colitis and colorectal cancer. A population based study","volume":"323","author":"Ekbom","year":"1990","journal-title":"N Engl J Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994611002935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994611002935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/6\/4\/476\/1180751\/6-4-476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T11:18:24Z","timestamp":1560943104000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2011.10.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1873994611002935"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2011.10.006","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}